Glucose Variability and β-Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lin, Chia Hung ^a,b   Hsieh, Sheng Hwu ^a   Sun, Jui Hung ^a   Tsai, Jir Shiong ^c   Huang, Yu Yao ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c Sun Yat Sen Cancer Center   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C PEPTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; INSULIN; PEPTIDE; VENOM;

AGONISTS; BIOASSAY; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN INFUSION; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ADIPONECTIN; BIOMARKERS; BLOOD GLUCOSE; C-PEPTIDE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDPOINT DETERMINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PEPTIDES; RISK FACTORS; VENOMS;

EID: 84947934831     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16968     Document Type: Article

References (22)

1. Baggio, L. L., Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology. 132, 2131-2157 (2007).
2. Holst, J. J. et al. Proglucagon processing in porcine and human pancreas. J Biol Chem. 269, 18827-18833. (1994).
3. Drucker, D. J., Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368, 1696-1705. (2006).
4. Egan, J. M., Clocquet, A. R., Elahi, D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 87, 1282-1290. (2002).
5. Buse, J. B. et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 154, 103-112. doi: 110.7326/0003-4819-7154-7322-201101180-201100300. Epub 201102010 Dec 201101186. (2011).
6. Bode, B. W. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. Clin Ther. 29, S135-144. doi: 110.1016/j.clinthera.2007.1012.1013. (2007).
7. Lin, C. H. et al. Effects of a novel short-term continuous subcutaneous insulin infusion program evaluated by continuous glucose monitoring on young adult type 1 diabetic patients in Taiwan. Endocr J. 58, 835-840 (2011).
8. Meier, J. J. et al. Functional assessment of pancreatic beta-cell area in humans. Diabetes. 58, 1595-1603. doi: 1510.2337/db1508-1611. Epub 2009 Jun 1599. (2009).
9. Arnolds, S. et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 33, 1509-1515. doi: 1510.2337/dc1509-2191. Epub 2010 Mar 1531. (2010).
10. Yoon, N. M., Cavaghan, M. K., Brunelle, R. L., Roach, P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 31, 1511-1523. doi: 1510.1016/j. clinthera.2009.1507.1021. (2009).
11. Davis, S. N. et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care. 30, 2767-2772. Epub 2007 Jun 2726. (2007).
12. De Natale, C. et al. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. Diabetes Care. 32, 2168-2173. doi: 2110.2337/dc2109-0266. Epub 2009 Sep 2169. (2009).
13. Colagiuri, S. 2011 Guideline for Management of PostMeal Glucose in Diabetes. International Diabetes Federation ISBN 2-930229-81-0 (2011).
14. Ceriello, A. et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res. 30, 146-149. (1998).
15. Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990 s. Nature. 362, 801-809 (1993).
16. Monnier, L. et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 53, 562-571. doi: 510.1007/s00125-00009-01574-00126. Epub 02009 Nov 00125. (2010).
17. Courreges, J. P. et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med. 25, 1129-1131. doi: 1110.1111/j.1464-5491.2008.02484.x. (2008).
18. Kim Chung le,T. et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun. 390, 613-618. doi: 610.1016/j. bbrc.2009.1010.1015. Epub 2009 Oct 1020. (2009).
19. Matsuda, M., DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 22, 1462-1470. (1999).
20. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28, 412-419. (1985).
21. Bode, B. W., Tamborlane, W. V., Davidson, P. C. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med. 111, 69-77; quiz 27. (2002).
22. Monnier, L. et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Jama. 295, 1681-1687. (2006).